Patents by Inventor Mangesh Sadashiv Bordawekar

Mangesh Sadashiv Bordawekar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
    Publication number: 20210169854
    Abstract: Disclosed are novel pharmaceutical formulation containing 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid or a pharmaceutically acceptable salt thereof and processes for preparing the same.
    Type: Application
    Filed: September 18, 2020
    Publication date: June 10, 2021
    Inventors: Mangesh Sadashiv Bordawekar, Stephanie Kay Dodd, Cornelius Stephan Harlacher, Jithin K John, Pravin Karmuse, Saran Kumar, Sangeetha Kumari, Vishnu Maremanda, Parthkumar Patel, Kanhaiyalal Patidar, Kapil Patil, Alan Edward Royce, Shaikh Mohsin Shaikh Hamid, Mauro Serratoni, Henricus Lambertus Gerardus Maria Tiemessen, Daya D Verma, Sunita Yadav
  • Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
    Patent number: 9301957
    Abstract: A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: April 5, 2016
    Assignee: Novartis AG
    Inventors: Upkar Bhardwaj, Ann Reese Comfort, Ping Li, Shoufeng Li, Alexey Makarov, Mangesh Sadashiv Bordawekar
  • IMMEDIATE RELEASE 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide FORMULATION
    Publication number: 20150320749
    Abstract: A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1 H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed
    Type: Application
    Filed: May 9, 2014
    Publication date: November 12, 2015
    Inventors: Upkar Bhardwaj, Ann Reese Comfort, Ping Li, Shoufeng Li, Alexey Makarov, Mangesh Sadashiv Bordawekar